Yesterday, Thermo Fisher Scientific opened its first Innovation Lab in Center Valley, Pennsylvania., as a space where partners can come together to collaborate, innovate, and ideate on solutions to the biggest clinical supply chain pain points.
There is an urgent and unmet need to better understand the features of acute respiratory distress syndrome (ARDS), which is why a clinical research business has been selected to start a phase 2 platform clinical trial to investigate it further.
OSP was delighted to speak to Galina Nesterova, executive medical director at the Rare Disease & Pediatrics Center of Excellence, and Susan McCune, vice president of pediatrics and clinical pharmacology both within medical science and strategy at...
With so many advanced therapies on the horizon, the next few years are poised to be one of significant progress for patients with over 2000 cell and gene therapies in active clinical trials globally.
Thermo Fisher Scientific’s clinical service unit PPD has won some “very large” customers since becoming part of the broader group in a mega-merger, according to CEO Marc Casper.
The latest news on software, manufacturing solutions, partnerships, and more includes IQVIA, TFF Pharmaceuticals, Quotient Sciences and other key companies.
Changing to DCT is more than merely flipping a switch; two leaders from the Thermo Fisher Scientific business offer advice for implementing the format.
This month’s list of announcements about technology, funding, and more includes Medable, Clarify Health, Thermo Fisher Scientific, and other key companies.
During CPhI Worldwide, leaders from two organizations will outline how CM is taking off, potential benefits, and how to clear common obstacles to adoption.
An academic researcher and and company expert discuss on how evolving cryogenic electron microscopy has led to high resolutions and accelerated results.
A representative from Thermo Fisher Scientific addresses how bringing research and resources directly to participants can address problems with studies.
The chairman, president and CEO of Thermo Fisher says the acquisition stands to benefit clinical trial and drug development clients in a long list of ways.
The science service and technologies firm plans to bring the CRO under its Laboratory Products and Services Segment umbrella after the deal is completed.
The direct-to-patient service is designed to support trials and help to minimize trial length and costs, while boosting enrollment and participation rates.
Thermo Fisher Scientific doubles the capacity of its gene therapy and viral vector processing facility in Alachua, Florida, to provide scalability to customers.
Regardless of the quality of the raw materials used in bioproduction processes, variability is a very common threat that can be addressed, says Thermo Fisher executive.
Oncology and immunotherapies are the top two indications for global clinical research – and are driving a significant growth in the market demand for HPAPIs, says Patheon executive.
Sponsors using a single-source outsourcing partner could potentially save up to $45m through reduced time to market, according to a recent Tufts study.
Patheon is “better positioned” to serve clients following the Thermo Fisher Scientific Inc. acquisition, says CDMO president, whose initial focus will be integration.
The laboratories will participate in oncology-focused clinical trials as the program’s preferred partners and will be among the first to access Thermo Fisher’s pipeline of novel platforms and assays.
Patheon NV has announced it will spend $45m to expand and enhance its manufacturing network citing customer demand for more reliable, flexible and cost-efficient supply chains.
Thermo Fisher Scientific, Inc. saw revenue grow 8% in 2016, mostly due to acquisitions of new Chromotography and mass spectrometry tech and expanding its Bioproduction.
Thermo Fisher Scientific has revealed a preemptive pharmacogenomic risk factor screening tool to help increase drug development outcome efficiency and reduce adverse drug reactions.
Chinese authorities have given Thermo Fisher Scientific the green light to buy Life Technologies on the condition it discounts certain products sold in the coutry.
Outsourcing-Pharma.com presents its weekly round-up of the latest movers and shakers in the world of pharmaceuticals, including news from Chiltern, Thermo Fisher and Penn Pharma.
Proposed changes to USP chapters 232 and 233 on trace impurities would increase drug industry use of automated analysis, creating “huge number” of potential new customers says Thermo Fisher Scientific.
Japanese researchers look set to have another option for biomarker analysis, after Thermo Fisher Scientific unveils plans for Tokyo research laboratory unit.
German pharmaceutical firm Merck KGaA says proposed Millipore acquisition will transform its chemicals unit and give it a more balanced business profile.
US group Thermo Fisher Scientific and industrial engineering giant Siemens have teamed up to offer the pharmaceutical industry a new way of assessing processes used during early drug development, manufacturing scale up and commercial production.
St Patrick’s Day celebrations weren’t the only thing bringing people together in New York last week as the pharmaceutical manufacturing and outsourcing industries gathered at the Jacob K Javits convention centre for Interphex 2009.
